Immunotherapy Drugs Market by Drug Type (Adult Vaccines, Monoclonal Antibodies, Checkpoint Inhibitors, Interleukins, Interferon Alpha & Beta, and Others), by Therapeutic Application (Autoimmune & Inflammatory Diseases, Cancer, Infectious Diseases, and Others), and by End-User (Hospitals, Clinics, and Others)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2018—2025

                                          
Abstract
                    
The report covers a forecast and an analysis of the immunotherapy drugs market on a global and regional level. The study provides historical data from 2016, 2017, and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints for the immunotherapy drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the immunotherapy drugs market on a global and regional level.

In order to give the users of this report a comprehensive view of the immunotherapy drugs market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the immunotherapy drugs market on a global and regional basis.

The study provides a decisive view of the immunotherapy drugs market by segmenting the market based on drug type, therapeutic applications, end-user, and region. By drug type, the market is segmented into adult vaccines, monoclonal antibodies, checkpoint inhibitors, interleukins, interferon alpha and beta, and others. Preventive vaccines and therapeutic vaccines comprise the adult vaccines segment. By therapeutic application, this global market is segmented into autoimmune and inflammatory diseases, cancer, infectious diseases, and others. Cancer segment is further divided into the solid tumor and malignant. Hospitals, clinics, and others form the end-user segment of the global immunotherapy drugs market.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S. Canada, Germany, France, the UK, China, Japan, India, and Brazil.

Some key players of the immunotherapy drugs market include F. Hoffmann-La Roche AG, Amgen, Inc., Novartis International AG, AbbVie, Inc., Merck & Co., Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, and Johnson & Johnson, among others.

This report segments the global immunotherapy drugs market into:

Global Immunotherapy Drugs Market: By Drug Type

	Monoclonal Antibodies
	Adult Vaccines
	
		Preventive Vaccines
		Therapeutic Vaccines
	
	
	Checkpoint Inhibitors
	Interferons Alpha and Beta
	Interleukins
	Others

Global Immunotherapy Drugs Market: By Therapeutic Application

	Cancer
	
		Solid Tumor
		Malignant
	
	
	Autoimmune and Inflammatory Diseases
	Infectious Diseases
	Others

Global Immunotherapy drugs Market: By End-User

	Hospitals
	Clinics
	Others

Global Immunotherapy Drugs Market: By Region

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	Middle East and Africa